Vuity eye drops price list

Vuity eye drops are the world's first prescription eye drops approved to treat presbyopia. The price difference between its original drug and generic drugs significantly affects patients' medication choices. The original drug is produced by the American company Allergan, and is priced at about US$159 per box for 2.5ml, while the prices of generic drugs already on the market in some countries are relatively low. At present, this product has not been approved for marketing in mainland China, and naturally it is not included in the scope of national medical insurance reimbursement.

Vuity eye drops original drug and generic drug prices

The market prices vary significantly depending on the source of the drug. Understanding this price information can help patients make economical and reasonable medication choices.

Original drug price

Original Vuity eye drops produced by the American company Allergan are officially priced at US$159 per box for 2.5ml. The price reflects the research and development costs and patent protection value of innovative drugs, with the average daily treatment cost being approximately US$5.3.

Price of generic drugs

In countries such as India that allow generic drugs to be put on the market, the price of Vuity generic drugs with the same specifications is about 30%-50% of the original drug. These generic drugs have passed bioequivalence tests and meet quality standards but save R&D investment.

The price difference is mainly due to R&D cost sharing and brand premium. Patients can choose a suitable version according to their economic status and treatment needs.

The domestic launch of Vuity Eye Drops

The launch of Vuity Eye Drops in mainland China is still in the early stages, and patient access channels are very limited.

Approval status

A query of the National Medical Products Administration database shows that Vuity eye drops have not yet submitted a new drug marketing application, and domestic pharmaceutical companies have no application records for related generic drugs.

Clinical use route

Individual medical institutions may introduce small quantities through temporary import procedures, but they need to meet specific conditions: necessary for treatment, no substitute drugs, single patient use, etc., and complete a complex approval process.

Since it has not been officially approved, domestic patients face many difficulties in obtaining Vuity eye drops, and in most cases they need to consider alternative treatment options.

The medical insurance reimbursement status of Vuity Eye Drops

As a drug that has not yet been approved in China, Vuity Eye Drops is naturally not included in any medical insurance reimbursement catalog, and patients must pay for it entirely out of their own pocket.

Conditions for medical insurance access

The National Medical Insurance Catalog only includes drugs that have been approved for marketing in China. Drugs need to pass multi-dimensional evaluations such as safety, effectiveness, and economics before they can enter the medical insurance negotiation process.

Cost Burden

Original drugs obtained through special channels cost approximately US$159 per box, which puts great financial pressure on patients who require long-term medication. Although generic drugs are cheaper, formal access channels are limited.

If Vuity eye drops can be approved for marketing in China in the future, it will have the opportunity to enter into medical insurance negotiations, but at this stage, patients need to bear all treatment costs.